Preventing infection-associated cancer: From bench to hillside

Journal of the National Cancer Institute

Volumn 97, Issue 4, 2005, Pages 245-246

  Goedert, James J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; ZIDOVUDINE; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER MORTALITY; CANCER RISK; DISEASE ASSOCIATION; DRUG MECHANISM; EDITORIAL; GENETIC VARIABILITY; HEPATITIS B; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; POPULATION GENETICS; PRIORITY JOURNAL; SCREENING TEST; SECONDARY PREVENTION; SERODIAGNOSIS; VACCINATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; ADULT; BLOOD; GENETICS; GENOTYPE; HEPATITIS B VIRUS; IMMUNOLOGY; INCIDENCE; ISOLATION AND PURIFICATION; LIVER TUMOR; MALE; NOTE; RISK ASSESSMENT; RISK FACTOR; TAIWAN; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; RISK ASSESSMENT; RISK FACTORS; TAIWAN; VIRAL LOAD;

EID: 13844322083     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji059     Document Type: Editorial

References (20)

1. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965;191:541-6.
2. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-4.
3. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol 1978;24:40-69.
4. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33.
5. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
6. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987;257:2597-603.
7. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
8. Lee CL, Hsieh KS, Ko YC. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003;12:57-9.
9. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
10. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-72.
11. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003;125:444-51.
12. Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004;40:790-2.
13. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
14. Gail MH, Rosenberg PS, Goedert JJ. Therapy may explain recent deficits in AIDS incidence. J Acquir Immune Defic Syndr 1990;3:296-306.
15. Wands JR. Prevention of hepatocellular carcinoma. N Engl J Med 2004;351:1567-70.
16. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, Version 2.0. No. 5 ed. Lyon (France); IARC Press, 2004.
17. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hepatitis viruses. Lyon France): IARC Press and WHO; 1994, p. 55-7.
18. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003;38:533-40.
19. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351:2832-8.
20. Kane MA. Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. Cancer Epidemiol Biomarkers Prev 2003;12:2-3.